Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014
This study aims to assess payments to private providers for HPV vaccination. We used the 2007–2014 MarketScan Commercial Claims and Encounters Database and included 3,456,180 HPV vaccination visits made by adolescents aged 11–17 years and enrolled in a non-capitated insurance plan in 37 states. We e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | Preventive Medicine Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211335519300920 |
| _version_ | 1818059651847028736 |
|---|---|
| author | Yuping Tsai Megan C. Lindley Fangjun Zhou Shannon Stokley |
| author_facet | Yuping Tsai Megan C. Lindley Fangjun Zhou Shannon Stokley |
| author_sort | Yuping Tsai |
| collection | DOAJ |
| description | This study aims to assess payments to private providers for HPV vaccination. We used the 2007–2014 MarketScan Commercial Claims and Encounters Database and included 3,456,180 HPV vaccination visits made by adolescents aged 11–17 years and enrolled in a non-capitated insurance plan in 37 states. We examined insurance reimbursements and its time trend for vaccine purchase and vaccine administration. Using the vaccine purchase price published by the Centers for Disease Control and Prevention (CDC) and the vaccination payment recommended by the American Academy of Pediatrics (AAP), we evaluated the financial concerns of administering HPV vaccines among private providers. In 2007–2014, the mean vaccine purchase reimbursement was $159.17 and the mean vaccine administration reimbursement was $23.91. During the study period, vaccine purchase reimbursements did not significantly change, but vaccine administration reimbursements increased. On average, 89.9% of the HPV claims received vaccine purchase reimbursements greater than the CDC-published price and 14.1% of HPV claims received vaccine purchase reimbursements above the AAP-recommended payment. Our results suggest that private providers are likely to receive sufficient reimbursements to cover the costs of administering HPV vaccines. However, the profit margin is likely to be small. Keywords: Human papillomavirus, Vaccines, Reimbursements |
| first_indexed | 2024-12-10T13:19:55Z |
| format | Article |
| id | doaj.art-3bbfc4ae85114a0ab42838379cfb7469 |
| institution | Directory Open Access Journal |
| issn | 2211-3355 |
| language | English |
| last_indexed | 2024-12-10T13:19:55Z |
| publishDate | 2019-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Preventive Medicine Reports |
| spelling | doaj.art-3bbfc4ae85114a0ab42838379cfb74692022-12-22T01:47:22ZengElsevierPreventive Medicine Reports2211-33552019-09-0115Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014Yuping Tsai0Megan C. Lindley1Fangjun Zhou2Shannon Stokley3Corresponding author at: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A19, Atlanta, GA 30329, United States.; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaThis study aims to assess payments to private providers for HPV vaccination. We used the 2007–2014 MarketScan Commercial Claims and Encounters Database and included 3,456,180 HPV vaccination visits made by adolescents aged 11–17 years and enrolled in a non-capitated insurance plan in 37 states. We examined insurance reimbursements and its time trend for vaccine purchase and vaccine administration. Using the vaccine purchase price published by the Centers for Disease Control and Prevention (CDC) and the vaccination payment recommended by the American Academy of Pediatrics (AAP), we evaluated the financial concerns of administering HPV vaccines among private providers. In 2007–2014, the mean vaccine purchase reimbursement was $159.17 and the mean vaccine administration reimbursement was $23.91. During the study period, vaccine purchase reimbursements did not significantly change, but vaccine administration reimbursements increased. On average, 89.9% of the HPV claims received vaccine purchase reimbursements greater than the CDC-published price and 14.1% of HPV claims received vaccine purchase reimbursements above the AAP-recommended payment. Our results suggest that private providers are likely to receive sufficient reimbursements to cover the costs of administering HPV vaccines. However, the profit margin is likely to be small. Keywords: Human papillomavirus, Vaccines, Reimbursementshttp://www.sciencedirect.com/science/article/pii/S2211335519300920 |
| spellingShingle | Yuping Tsai Megan C. Lindley Fangjun Zhou Shannon Stokley Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 Preventive Medicine Reports |
| title | Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 |
| title_full | Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 |
| title_fullStr | Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 |
| title_full_unstemmed | Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 |
| title_short | Insurance reimbursements for human papillomavirus vaccination in the private sector, 2007–2014 |
| title_sort | insurance reimbursements for human papillomavirus vaccination in the private sector 2007 2014 |
| url | http://www.sciencedirect.com/science/article/pii/S2211335519300920 |
| work_keys_str_mv | AT yupingtsai insurancereimbursementsforhumanpapillomavirusvaccinationintheprivatesector20072014 AT meganclindley insurancereimbursementsforhumanpapillomavirusvaccinationintheprivatesector20072014 AT fangjunzhou insurancereimbursementsforhumanpapillomavirusvaccinationintheprivatesector20072014 AT shannonstokley insurancereimbursementsforhumanpapillomavirusvaccinationintheprivatesector20072014 |